Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 51,588 shares of the biopharmaceutical company’s stock after acquiring an additional 10,100 shares during the period. KLP Kapitalforvaltning AS’s holdings in Regeneron Pharmaceuticals were worth $29,006,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Marino Stram & Associates LLC increased its holdings in shares of Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 20 shares during the period. CoreCap Advisors LLC grew its position in Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 20 shares during the last quarter. Strait & Sound Wealth Management LLC grew its position in Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 21 shares during the last quarter. CX Institutional increased its stake in Regeneron Pharmaceuticals by 7.9% in the 2nd quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 22 shares during the period. Finally, Independence Bank of Kentucky raised its position in Regeneron Pharmaceuticals by 7.7% during the 3rd quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock worth $173,000 after buying an additional 22 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 4.6%

Shares of Regeneron Pharmaceuticals stock opened at $812.27 on Thursday. The company has a 50-day moving average of $732.29 and a two-hundred day moving average of $624.86. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $814.10. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The stock has a market cap of $85.37 billion, a PE ratio of 19.45, a price-to-earnings-growth ratio of 2.32 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the prior year, the firm posted $12.46 EPS. The company’s revenue was up .9% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a $0.88 dividend. The ex-dividend date was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 7.02% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. HSBC assumed coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $255.00 target price on the stock. Finally, UBS Group raised their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $790.05.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded REGN from Underperform to Buy and raised its price target to $860, citing improving fundamentals across key products and several potential 2026 catalysts—this upgrade and higher target are the primary near-term catalyst for the rally. Regeneron Pharmaceuticals upgraded by Bank of America
• Positive Sentiment: Benzinga and other outlets highlighted the upgrade and analyst reasoning, increasing investor attention and momentum behind the stock move. Regeneron Just Moved From Underperform To Buy – Here’s Why
• Positive Sentiment: Zacks highlights Regeneron’s strong history of earnings surprises and currently favorable indicators that increase the odds of another beat, which supports investor confidence ahead of the next report. Will Regeneron (REGN) Beat Estimates Again?
• Neutral Sentiment: Industry comparisons and valuation pieces (REGN vs ILMN) are circulating; these help frame Regeneron’s relative value but are secondary to the upgrade news. REGN vs. ILMN: Which Stock Is the Better Value Option?
• Neutral Sentiment: Additional sector commentary and head‑to‑head analyses (e.g., vs. Atea) and broader analyst-blog notes on AI in healthcare provide context but are unlikely to move the stock as much as the BoA upgrade. Regeneron vs Atea head-to-head Zacks Analyst Blog
• Negative Sentiment: Some previews warn analysts expect a double-digit profit dip in the upcoming quarter—this is a risk heading into earnings and could cap upside if results disappoint. Quarterly earnings preview

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.